Chemistry & Biology 2008-08-25

Deciphering deazapurine biosynthesis: pathway for pyrrolopyrimidine nucleosides toyocamycin and sangivamycin.

Reid M McCarty, Vahe Bandarian

Index: Chem. Biol. 15(8) , 790-8, (2008)

Full Text: HTML

Abstract

Pyrrolopyrimidine nucleosides analogs, collectively referred to as deazapurines, are an important class of structurally diverse compounds found in a wide variety of biological niches. In this report, a cluster of genes from Streptomyces rimosus (ATCC 14673) involved in production of the deazapurine antibiotics sangivamycin and toyocamycin was identified. The cluster includes toyocamycin nitrile hydratase, an enzyme that catalyzes the conversion of toyocamycin to sangivamycin. In addition to this rare nitrile hydratase, the cluster encodes a GTP cyclohydrolase I, linking the biosynthesis of deazapurines to folate biosynthesis, and a set of purine salvage/biosynthesis genes, which presumably convert the guanine moiety from GTP to the adenine-like deazapurine base found in toyocamycin and sangivamycin. The gene cluster presented here could potentially serve as a model to allow identification of deazapurine biosynthetic pathways in other bacterial species.


Related Compounds

Related Articles:

Synthesis and in vitro antitumor activity of some amino-deoxy 7-hexofuranosylpyrrolo[2,3-d]pyrimidines.

1998-06-01

[Carbohydr. Res. 308(3-4) , 319-28, (1998)]

Kinetics and localization of the phosphorylation of rhodopsin by protein kinase C.

1995-03-24

[J. Biol. Chem. 270(12) , 6710-7, (1995)]

Synthesis of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. Isosteres of sangivamycin, tubercidin, and toyocamycin.

2001-03-09

[Carbohydr. Res. 331(1) , 77-82, (2001)]

Shape changes and chemokinesis of Walker carcinosarcoma cells: effects of protein kinase inhibitors (HA-1004, polymyxin B, sangivamycin and tamoxifen) and an inhibitor of diacylglycerol kinase (R 59022).

1993-01-01

[Anticancer Res. 13(2) , 347-54, (1993)]

Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.

2012-11-01

[Mol. Cancer Ther. 11(11) , 2321-30, (2012)]

More Articles...